Keywords: nycomed, licenses, rights, ciclesonide, drugs, sepracor, deal
Nycomed licenses US rights to ciclesonide drugs to Sepracor in deal worth up to $430M
Article | 04 February 2008
Danish drugmaker Nycomed has granted Sepracor exclusive development, marketing and commercialization rights for its novel corticosteroid ciclesonide in the latter's ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
